Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine

2021166 citationsJournal Articlehybrid Open Access

Authors

Keith W. Pratz · University of Pennsylvania

Brian A. Jonas · University of California, Davis

Vinod Pullarkat · Université Toulouse III - Paul Sabatier

Christian Récher · Université Toulouse III - Paul Sabatier

Andre C. Schuh · Princess Margaret Cancer Centre

Michael J. Thirman · University of Chicago

Jacqueline S. Garcia

Abstract

Patients who achieved CRc and MRD < 10<sup>-3</sup> with venetoclax and azacitidine had longer DoR, EFS, and OS, than responding patients with MRD ≥ 10<sup>-3</sup>.

Topics & Keywords

Acute Myeloid Leukemia Research Myeloproliferative Neoplasms: Diagnosis and Treatment Hematopoietic Stem Cell Transplantation

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 40, Issue 8, pp. 855-865

DOI: 10.1200/jco.21.01546

Field-Weighted Citation Impact: 17.42